CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Combination of Veliparib + Lapatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02158507
NCT02158507N/ACompleted
CompareCT.gov

An Open Label, Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer

University of Alabama at Birmingham·interventional·Posted Jun 9, 2014·Updated Jan 22, 2026

In Brief

A clinical study evaluating Combination of Veliparib + Lapatinib for Metastatic Triple Negative Breast Cancer. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This study will evaluate the effectiveness and safety of the combination of two drugs, Veliparib and Lapatinib, given to participants with metastatic triple negative breast cancer that have undergone previous treatment. Veliparib is an investigational drug and has not been approved by the FDA while Lapatinib has been approved by the FDA for another type of breast cancer. All eligible participants will receive the study medications and not a placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Triple Negative Breast Cancer
CountriesUnited States
CollaboratorsBreast Cancer Research Foundation of Alabama, GlaxoSmithKline, AbbVie

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 9, 2014
Enrollment StartSep 4, 2014
Primary CompletionJul 22, 2021
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 12.1 years ago

Interventions

Combination of Veliparib + Lapatinibdrug

Treatment cannot be in administered conjunction with other chemotherapy, targeted therapy, radiation therapy, or other investigational drugs.